ADC 3680B

Drug Profile

ADC 3680B

Alternative Names: ADC3680; ADC3680B; PTR-36

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pulmagen Therapeutics
  • Developer Pulmagen Therapeutics; Teijin
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic asthma; Asthma
  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in United Kingdom (PO, Tablet)
  • 29 Jul 2015 Phase-II development is ongoing for Asthma in USA and Europe
  • 07 Dec 2014 Pulmagen Therapeutics completes a phase II trial in Asthma in USA, Croatia, Czech Republic, Germany, Hungary and Poland (NCT01730027)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top